Latest Revenue Guidance News

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Temple & Webster has delivered its most profitable April ever with EBITDA hitting around $2.5 million, setting the stage for a near doubling of earnings in FY27 despite weak consumer confidence.

Archer Materials is progressing toward demonstrating a working qubit this year while scaling quantum device fabrication from lab prototypes to wafer-scale manufacturing using semiconductor industry standards.

EBR Systems accelerated its U.S. commercial rollout of the WiSE CRT System in Q1 2026 with implant volumes more than doubling and revenue hitting US$2.4 million. The company also secured a key regulatory milestone in Australia with TGA Priority Review, yet losses deepened and cash burn intensified, raising fresh questions about its funding runway.

Life360 surged to $143.1 million in Q1 2026 revenue, powered by 27% growth in paying subscribers and a 329% jump in advertising following the Nativo acquisition. The company raised its full-year guidance as it navigates temporary user growth headwinds.

CSL Limited’s interim CEO Gordon Naylor reveals a downgraded FY26 outlook amid slower growth and announces substantial impairments tied to CSL Vifor assets. Leadership changes and transformation efforts aim to restore momentum.

Schoolblazer reports a modest revenue dip to $55.4m in 1H FY26 amid supply chain and geopolitical headwinds but strengthens its balance sheet with a new $110 million credit facility and advances integration efforts targeting profitability in FY27.

EVZ Limited projects full year revenue between $120 million and $125 million for FY26, alongside an EBITDA forecast of $8.5 million to $9 million, reflecting improved margins and operational efficiency.

Me Today has raised its full-year revenue forecast to over NZD 7.4 million, driven by strong domestic sales and a new exclusive distribution deal in Southeast Asia. The nutritional supplements company also expects a 25% reduction in EBITDA loss, reflecting tighter cost control amid ongoing product innovation.

Acusensus Limited maintains its FY26 revenue and EBITDA guidance while advancing multiple enforcement programs across the US, UK, New Zealand, and Australia, underpinned by new product developments and international growth.

Resonance Health upgrades its FY26 underlying EBITDA guidance to $2.6 million, driven by operational efficiencies and growth in its Software-as-Medical Devices segment, despite a slight revenue timing delay.

NRW Holdings has reaffirmed its FY26 guidance with revenue expected between $4.1 billion and $4.2 billion and underlying EBITA of $275 million to $285 million, supported by a robust $7.5 billion order book and strategic acquisitions in energy transition and digital innovation.